OCD and BFRBs can look alike, but they’re not the same. Discover the similarities, important distinctions, and what they mean for treatment and recovery.

Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech focused on artificial intelligence (AI), became a publicly traded company ...

Discover how noticing meaningful coincidences, or synchronicities, can guide your path and reveal insight in everyday life.

Recursion Pharmaceuticals (RXRX) closed at $4.77 in the latest trading session, marking a -1.24% move from the prior day. This change lagged the S&P 500's 0.47% gain on the day. Meanwhile, the Dow ...

Samsung Medical Center announced that its researchers have developed a new AI model capable of predicting the recurrence risk of non-small cell lung cancer up to a year in advance. According to the ...

Department of Neurosurgery, Changde Hospital, Xiangya School of Medicine, Central South University (The First People’s Hospital of Changde City), Changde, China Background: Chronic subdural hematoma ...

1 Department of Cardiology, National University Heart Centre Singapore, Singapore 2 Department of Medicine, National University Hospital, Singapore 3 Division of Neurology, Department of Medicine, ...

Copyright: © 2025 The Author(s). Published by Elsevier Ltd. Between Nov 23, 2006, and Dec 20, 2013, 660 eligible and evaluable patients recruited at 103 centres in ...

Welcome to this afternoon session with Recursion. My name is Andrew Pucher. I'm part of the Healthcare Investment Banking team, and I'm joined by Ben Taylor, CFO of Recursion; and Sara Sherman, Head ...

Abstract: This research explores deep learning-based time series forecasting techniques to predict the S&P 500 Index tracking the stock performance of 500 leading companies listed on stock exchanges ...

Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, ...

Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, ...